Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 7/2016

01-07-2016 | Original Article

MicroRNA-503 represses epithelial–mesenchymal transition and inhibits metastasis of osteosarcoma by targeting c-myb

Authors: Xinzhen Guo, Jie Zhang, Jianfeng Pang, Sheng He, Guojun Li, Yang Chong, Chao Li, Zhijian Jiao, Shiqian Zhang, Ming Shao

Published in: Tumor Biology | Issue 7/2016

Login to get access

Abstract

Deregulated expression of miRNAs contributes to the development of osteosarcoma. Our previous study has showed that miR-503 was downregulated in osteosarcoma tissues. However, the mechanism of the miR-503 in osteosarcoma development still remains largely undefined. In our study, we found that miR-503 overexpression suppressed cell invasion and migration and inhibited epithelial-to-mesenchymal transition (EMT) of MG-63. Furthermore, we identified that c-myb, an oncogene, was a direct target of miR-503. Moreover, overexpression of c-myb could rescue miR-503-suppressed invasion and EMT. The expression of c-myb was upregulated in osteosarcoma cell lines. Therefore, we conclude that high miR-503 expression suppressed osteosarcoma cell mobility and EMT through targeting c-myb, and this may serve as a therapeutic target.
Appendix
Available only for authorised users
Literature
1.
Hu K, Liao D, Wu W, Han AJ, Shi HJ, Wang F, et al. Targeting the anaphase-promoting complex/cyclosome (apc/c)-bromodomain containing 7 (brd7) pathway for human osteosarcoma. Oncotarget. 2014;5:3088–100.CrossRefPubMedPubMedCentral
2.
Tsai HC, Su HL, Huang CY, Fong YC, Hsu CJ, Tang CH. Ctgf increases matrix metalloproteinases expression and subsequently promotes tumor metastasis in human osteosarcoma through down-regulating mir-519d. Oncotarget. 2014;5:3800–12.CrossRefPubMedPubMedCentral
3.
Tang J, Shen L, Yang Q, Zhang C. Overexpression of metadherin mediates metastasis of osteosarcoma by regulating epithelial-mesenchymal transition. Cell Prolif. 2014;47:427–34.CrossRefPubMed
4.
Montanaro L, Mazzini G, Barbieri S, Vici M, Nardi-Pantoli A, Govoni M, et al. Different effects of ribosome biogenesis inhibition on cell proliferation in retinoblastoma protein- and p53-deficient and proficient human osteosarcoma cell lines. Cell Prolif. 2007;40:532–49.CrossRefPubMed
5.
Han G, Wang Y, Bi W. C-myc overexpression promotes osteosarcoma cell invasion via activation of mek-erk pathway. Oncol Res. 2012;20:149–56.CrossRefPubMed
6.
Ye Z, Jingzhong L, Yangbo L, Lei C, Jiandong Y. Propofol inhibits proliferation and invasion of osteosarcoma cells by regulation of microrna-143 expression. Oncol Res. 2014;21:201–7.CrossRef
7.
Yan K, Gao J, Yang T, Ma Q, Qiu X, Fan Q, et al. MicroRNA-34a inhibits the proliferation and metastasis of osteosarcoma cells both in vitro and in vivo. PLoS One. 2012;7:e33778.CrossRefPubMedPubMedCentral
8.
Zhao G, Cai C, Yang T, Qiu X, Liao B, Li W, et al. MicroRNA-221 induces cell survival and cisplatin resistance through pi3k/akt pathway in human osteosarcoma. PLoS One. 2013;8:e53906.CrossRefPubMedPubMedCentral
9.
Namlos HM, Meza-Zepeda LA, Baroy T, Ostensen IH, Kresse SH, Kuijjer ML, et al. Modulation of the osteosarcoma expression phenotype by micrornas. PLoS One. 2012;7:e48086.CrossRefPubMedPubMedCentral
10.
Ji F, Zhang H, Wang Y, Li M, Xu W, Kang Y, et al. MicroRNA-133a, downregulated in osteosarcoma, suppresses proliferation and promotes apoptosis by targeting bcl-xl and mcl-1. Bone. 2013;56:220–6.CrossRefPubMed
11.
Liang J, Zhang Y, Jiang G, Liu Z, Xiang W, Chen X, et al. Mir-138 induces renal carcinoma cell senescence by targeting ezh2 and is downregulated in human clear cell renal cell carcinoma. Oncol Res. 2013;21:83–91.CrossRefPubMed
12.
Zhou J, Song S, Cen J, Zhu D, Li D, Zhang Z. MicroRNA-375 is downregulated in pancreatic cancer and inhibits cell proliferation in vitro. Oncol Res. 2012;20:197–203.CrossRefPubMed
13.
Fei B, Wu H. Mir-378 inhibits progression of human gastric cancer mgc-803 cells by targeting mapk1 in vitro. Oncol Res. 2012;20:557–64.CrossRefPubMed
14.
Bier A, Giladi N, Kronfeld N, Lee HK, Cazacu S, Finniss S, et al. MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting rtvp-1. Oncotarget. 2013;4:665–76.CrossRefPubMedPubMedCentral
15.
Li H, Yang BB. Stress response of glioblastoma cells mediated by mir-17-5p targeting pten and the passenger strand mir-17-3p targeting mdm2. Oncotarget. 2012;3:1653–68.CrossRefPubMedPubMedCentral
16.
McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Franklin RA, Montalto G, et al. Ras/raf/mek/erk and pi3k/pten/akt/mtor cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget. 2012;3:1068–111.CrossRefPubMedPubMedCentral
17.
Lee HK, Finniss S, Cazacu S, Bucris E, Ziv-Av A, Xiang C, et al. Mesenchymal stem cells deliver synthetic microRNA mimics to glioma cells and glioma stem cells and inhibit their cell migration and self-renewal. Oncotarget. 2013;4:346–61.CrossRefPubMedPubMedCentral
18.
Yu X, Li Z. MicroRNAs regulate vascular smooth muscle cell functions in atherosclerosis (review). Int J Mol Med. 2014;34:923–33.PubMed
19.
Yang WB, Chen PH, Hsu TS, Fu TF, Su WC, Liaw H, et al. Sp1-mediated microRNA-182 expression regulates lung cancer progression. Oncotarget. 2014;5:740–53.CrossRefPubMedPubMedCentral
20.
Akiyoshi S, Fukagawa T, Ueo H, Ishibashi M, Takahashi Y, Fabbri M, et al. Clinical significance of mir-144-zfx axis in disseminated tumour cells in bone marrow in gastric cancer cases. Br J Cancer. 2012;107:1345–53.CrossRefPubMedPubMedCentral
21.
Luo J, Cai Q, Wang W, Huang H, Zeng H, He W, et al. A microRNA-7 binding site polymorphism in hoxb5 leads to differential gene expression in bladder cancer. PLoS One. 2012;7:e40127.CrossRefPubMedPubMedCentral
22.
Kulkarni S, Augoff K, Rivera L, McCue B, Khoury T, Groman A, et al. Increased expression levels of wave3 are associated with the progression and metastasis of triple negative breast cancer. PLoS One. 2012;7:e42895.CrossRefPubMedPubMedCentral
23.
Huang S, Xie Y, Yang P, Chen P, Zhang L. Hcv core protein-induced down-regulation of microRNA-152 promoted aberrant proliferation by regulating wnt1 in hepg2 cells. PLoS One. 2014;9:e81730.CrossRefPubMedPubMedCentral
24.
Li Z, Lei H, Luo M, Wang Y, Dong L, Ma Y, et al. DNA methylation downregulated mir-10b acts as a tumor suppressor in gastric cancer. Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2015;18:43–54.
25.
Yu X, Li Z, Shen J, Wu WK, Liang J, Weng X, et al. MicroRNA-10b promotes nucleus pulposus cell proliferation through rhoc-akt pathway by targeting hoxd10 in intervetebral disc degeneration. PLoS One. 2013;8:e83080.CrossRefPubMedPubMedCentral
26.
Li Z, Yu X, Shen J, Wu WK, Chan MT. MicroRNA expression and its clinical implications in ewing’s sarcoma. Cell Prolif. 2015;48:1–6.CrossRefPubMed
27.
Chong Y, Zhang J, Guo X, Li G, Zhang S, Li C, et al. MicroRNA-503 acts as a tumor suppressor in osteosarcoma by targeting l1cam. PLoS One. 2014;9:e114585.CrossRefPubMedPubMedCentral
28.
Huang J, Gao K, Lin J, Wang Q. MicroRNA-100 inhibits osteosarcoma cell proliferation by targeting cyr61. Tumour Biol J Int Soc Oncodev Biol Med. 2014;35:1095–100.CrossRef
29.
Wang X, Sun J, Fu C, Wang D, Bi Z: Microrna-214 regulates osteosarcoma survival and growth by directly targeting phosphatase and tensin homolog. Mol Med Rep. 2014.
30.
Cheng C, Chen ZQ, Shi XT. MicroRNA-320 inhibits osteosarcoma cells proliferation by directly targeting fatty acid synthase. Tumour Biol J Int Soc Oncodev Biol Med. 2014;35:4177–83.CrossRef
31.
Wang Y, Shang Y: Epigenetic control of epithelial-to-mesenchymal transition and cancer metastasis. Exp Cell Res. 2012.
32.
Koutsaki M, Spandidos DA, Zaravinos A. Epithelial-mesenchymal transition-associated mirnas in ovarian carcinoma, with highlight on the mir-200 family: prognostic value and prospective role in ovarian cancer therapeutics. Cancer Lett. 2014;351:173–81.CrossRefPubMed
33.
Cai LM, Lyu XM, Luo WR, Cui XF, Ye YF, Yuan CC, Peng QX, Wu DH, Liu TF, Wang E, Marincola FM, Yao KT, Fang WY, Cai HB, Li X: Ebv-mir-bart7-3p promotes the emt and metastasis of nasopharyngeal carcinoma cells by suppressing the tumor suppressor pten. Oncogene 2014.
34.
Tellez CS, Juri DE, Do K, Bernauer AM, Thomas CL, Damiani LA, et al. Emt and stem cell-like properties associated with mir-205 and mir-200 epigenetic silencing are early manifestations during carcinogen-induced transformation of human lung epithelial cells. Cancer Res. 2011;71:3087–97.CrossRefPubMedPubMedCentral
35.
Hur K, Toiyama Y, Takahashi M, Balaguer F, Nagasaka T, Koike J, et al. MicroRNA-200c modulates epithelial-to-mesenchymal transition (emt) in human colorectal cancer metastasis. Gut. 2013;62:1315–26.CrossRefPubMed
36.
Luo Z, Zhang L, Li Z, Jiang C, Dai Y, Liu X, et al. Mir-149 promotes epithelial-mesenchymal transition and invasion in nasopharyngeal carcinoma cells. Zhong Nan Da Xue Xue Bao Yi Xue Ban J Cent South Univ Med Sci. 2011;36:604–9.
37.
Cesi V, Casciati A, Sesti F, Tanno B, Calabretta B, Raschella G. Tgfbeta-induced c-myb affects the expression of emt-associated genes and promotes invasion of er+ breast cancer cells. Cell Cycle. 2011;10:4149–61.CrossRefPubMed
38.
Ren D, Wang M, Guo W, Zhao X, Tu X, Huang S, et al. Wild-type p53 suppresses the epithelial-mesenchymal transition and stemness in pc-3 prostate cancer cells by modulating mir145. Int J Oncol. 2013;42:1473–81.PubMed
39.
Chen RX, Xia YH, Xue TC, Ye SL. Transcription factor c-myb promotes the invasion of hepatocellular carcinoma cells via increasing osteopontin expression. J Exp Clin Cancer Res. 2010;29:172.CrossRefPubMedPubMedCentral
40.
41.
42.
Zhou Y, Ness SA. Myb proteins: angels and demons in normal and transformed cells. Front Biosci (Landmark Ed). 2011;16:1109–31.CrossRef
43.
Yongchun Z, Linwei T, Xicai W, Lianhua Y, Guangqiang Z, Ming Y, Guangjian L, Yujie L, Yunchao H: Microrna-195 inhibits non-small cell lung cancer cell proliferation, migration and invasion by targeting myb. Cancer Lett. 2014
44.
Lu H, Wang Y, Huang Y, Shi H, Xue Q, Yang S, et al. Expression and prognostic role of c-myb as a novel cell cycle protein in esophageal squamous cell carcinoma. Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mexico. 2013;15:796–801.
45.
Biroccio A, Benassi B, D’Agnano I, D’Angelo C, Buglioni S, Mottolese M, et al. C-myb and bcl-x overexpression predicts poor prognosis in colorectal cancer: clinical and experimental findings. Am J Pathol. 2001;158:1289–99.CrossRefPubMedPubMedCentral
46.
Kauraniemi P, Hedenfalk I, Persson K, Duggan DJ, Tanner M, Johannsson O, et al. Myb oncogene amplification in hereditary brca1 breast cancer. Cancer Res. 2000;60:5323–8.PubMed
47.
Karafiat V, Dvorakova M, Krejci E, Kralova J, Pajer P, Snajdr P, et al. Transcription factor c-myb is involved in the regulation of the epithelial-mesenchymal transition in the avian neural crest. Cell Mol Life Sci. 2005;62:2516–25.CrossRefPubMed
Metadata
Title
MicroRNA-503 represses epithelial–mesenchymal transition and inhibits metastasis of osteosarcoma by targeting c-myb
Authors
Xinzhen Guo
Jie Zhang
Jianfeng Pang
Sheng He
Guojun Li
Yang Chong
Chao Li
Zhijian Jiao
Shiqian Zhang
Ming Shao
Publication date
01-07-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 7/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-4797-4

Other articles of this Issue 7/2016

Tumor Biology 7/2016 Go to the issue

Original Article

Functional characterization of TRPM7 in nasopharyngeal carcinoma and its knockdown effects on tumorigenesis

Original Article

Diagnostic value of neutrophil gelatinase-associated lipocalin/matrix metalloproteinase-9 pathway in transitional cell carcinoma of the bladder

Original Article

Diagnostic significance of elevated expression of HBME-1 in papillary thyroid carcinoma

Original Article

High risk of development of renal cell tumor in end-stage kidney disease: the role of microenvironment

Original Article

YKL-40/chitinase-3-like protein 1 is associated with poor prognosis and promotes cell growth and migration of cholangiocarcinoma

Original Article

IKZF1 gene polymorphisms increased the risk of childhood acute lymphoblastic leukemia in an Iranian population
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits